Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Status:
Completed
Trial end date:
2016-02-25
Target enrollment:
Participant gender:
Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in
delaying tumor progression in patients with metastatic renal cell cancer after failure of one
first line regimen.